Victory Capital Management Inc. Makes New $19.44 Million Investment in Indivior PLC $INDV

Victory Capital Management Inc. purchased a new position in shares of Indivior PLC (NASDAQ:INDV) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 806,191 shares of the company’s stock, valued at approximately $19,437,000. Victory Capital Management Inc. owned approximately 0.58% of Indivior as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently made changes to their positions in the company. CWM LLC purchased a new position in Indivior in the 3rd quarter worth $25,000. Raymond James Financial Inc. bought a new position in shares of Indivior during the second quarter valued at about $26,000. Plato Investment Management Ltd bought a new position in shares of Indivior during the third quarter valued at about $52,000. Blue Trust Inc. purchased a new position in shares of Indivior in the third quarter worth about $99,000. Finally, California State Teachers Retirement System bought a new stake in shares of Indivior in the 2nd quarter valued at about $112,000. 60.33% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Indivior news, Director Keith Humphreys purchased 775 shares of the stock in a transaction that occurred on Monday, January 5th. The stock was bought at an average cost of $35.39 per share, with a total value of $27,427.25. Following the transaction, the director directly owned 5,802 shares in the company, valued at approximately $205,332.78. The trade was a 15.42% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Mark Stejbach acquired 775 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The shares were acquired at an average cost of $35.39 per share, for a total transaction of $27,427.25. Following the purchase, the director directly owned 16,847 shares of the company’s stock, valued at $596,215.33. This represents a 4.82% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders purchased 4,871 shares of company stock worth $172,385 over the last 90 days.

Indivior Stock Performance

Shares of NASDAQ:INDV opened at $33.34 on Wednesday. The firm has a market capitalization of $4.17 billion, a P/E ratio of 20.33 and a beta of 0.83. The stock has a 50 day moving average price of $33.99 and a 200-day moving average price of $30.51. Indivior PLC has a 52-week low of $8.64 and a 52-week high of $38.00.

Indivior (NASDAQ:INDV) last issued its quarterly earnings results on Thursday, February 26th. The company reported $0.82 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.17. The company had revenue of $358.00 million for the quarter, compared to analysts’ expectations of $305.62 million. Indivior had a negative return on equity of 148.76% and a net margin of 16.85%. On average, equities analysts forecast that Indivior PLC will post 1.22 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on INDV shares. Weiss Ratings raised Indivior from a “hold (c)” rating to a “buy (b-)” rating in a research note on Monday, March 2nd. HC Wainwright lifted their target price on shares of Indivior from $35.00 to $48.00 and gave the stock a “buy” rating in a research note on Monday, January 12th. Morgan Stanley reiterated an “overweight” rating and set a $36.00 price target on shares of Indivior in a report on Wednesday, December 3rd. Northland Securities set a $50.00 price target on shares of Indivior in a research report on Tuesday, January 20th. Finally, Zacks Research cut shares of Indivior from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 13th. Six research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $39.33.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.